Quick answer: In a major clinical trial, adults using once-weekly semaglutide 2.4 mg with lifestyle intervention lost an average of 14.9% of their starting weight after 68 weeks. However, results varied substantially: approximately 86% lost at least 5%, 69% lost at least 10%, and 51% lost at least 15%.[1]

A credible semaglutide “before and after” comparison should include more than photographs. Starting weight, percentage lost, treatment duration, dose, health conditions, lifestyle changes and whether treatment continued all matter.

Dramatic images online may be real, but they do not establish what the average person should expect.

Semaglutide results at a glance

Outcome after 68 weeks in STEP 1	Semaglutide	Placebo
Average weight change	-14.9%	-2.4%
Lost at least 5%	86.4%	31.5%
Lost at least 10%	69.1%	12.0%
Lost at least 15%	50.5%	4.9%

Participants did not receive medication alone. Both groups received lifestyle intervention, including counseling about reduced calorie intake and increased physical activity.[1]

These numbers describe groups in a controlled trial. They are not guaranteed personal outcomes.

What does 5%, 10% or 15% weight loss look like?

Percentage change is usually more useful than comparing pounds between people of different sizes.

Starting weight	5% loss	10% loss	15% loss	20% loss
180 lb	9 lb	18 lb	27 lb	36 lb
200 lb	10 lb	20 lb	30 lb	40 lb
225 lb	11.25 lb	22.5 lb	33.75 lb	45 lb
250 lb	12.5 lb	25 lb	37.5 lb	50 lb
300 lb	15 lb	30 lb	45 lb	60 lb

For example, someone starting at 250 pounds who lost the STEP 1 average of 14.9% would lose approximately 37 pounds and reach approximately 213 pounds.

That is an illustration—not a forecast.

To calculate your percentage:

Starting weight − current weight ÷ starting weight × 100

Someone who moves from 240 to 216 pounds has lost:

(240 − 216) ÷ 240 × 100 = 10%

What might change before the mirror looks different?

Many people notice functional or behavioral changes before seeing a dramatic visual transformation.

Early changes may include:

• Becoming full with smaller portions
• Fewer food cravings
• Less frequent snacking
• Reduced “food noise”
• A looser waistband
• Improved mobility
• Less breathlessness during routine activity
• Improved glucose or blood-pressure measurements

Photographs may not capture these changes. Clothing, camera angle, posture, lighting and water retention can also alter appearance.

A medically useful before-and-after assessment should include:

• Weight
• Percentage of starting weight lost
• Waist circumference
• Blood pressure
• Relevant laboratory results
• Medication dose and duration
• Physical function
• Side effects
• Ability to sustain the treatment plan

What realistic results may look like over time

There is no universal monthly weight-loss schedule. Injectable Wegovy is generally started at a low dose and increased gradually to improve tolerability. The first several months may therefore include dose escalation rather than maximum treatment exposure.

First month

Possible changes include:

• Earlier fullness
• Reduced appetite
• Mild gastrointestinal symptoms
• Small or no visible weight change

Not losing a dramatic amount during the first month does not establish treatment failure.

Months 2–4

As exposure and dose increase, some people see a clearer trend. Others lose slowly or require delayed escalation because of adverse effects.

This period may bring:

• More consistent portion reduction
• Increasing cumulative weight loss
• A looser fit around the waist
• Nausea or constipation following dose changes

Months 4–6

A sustained trend may become more apparent after adequate time at therapeutic doses. Lifestyle patterns, missed doses, tolerability and individual response become increasingly important.

Months 6–12

Weight may continue declining, but the rate commonly slows. In STEP 1, average weight approached its lowest level around week 60.[1]

One to two years

In STEP 5, participants receiving semaglutide 2.4 mg lost an average of 15.2% after 104 weeks, compared with 2.6% with placebo. Average loss plateaued around week 60 and was largely maintained while treatment continued.[2]

A stable weight after meaningful loss may therefore represent successful maintenance—not medication failure.

Why semaglutide before-and-after results vary

1. People begin at different weights

A 10% reduction equals 18 pounds for someone starting at 180 pounds and 30 pounds for someone starting at 300 pounds. Comparing pounds alone can be misleading.

2. Dose and treatment duration differ

Someone posting after 18 months at a maintenance dose cannot be fairly compared with someone still using an introductory dose after six weeks.

3. Diabetes can affect average results

Clinical trials involving people with type 2 diabetes have generally reported less average weight loss than trials involving adults without diabetes.[3] This does not mean semaglutide is ineffective for people with diabetes.

4. Lifestyle changes differ

Semaglutide reduces appetite and can make a calorie deficit easier to sustain, but food choices, liquid calories, alcohol, sleep and physical activity still influence results.

5. Medication adherence differs

Missed doses, supply interruptions, incorrect administration and unclear compounded-product concentrations can reduce exposure or create safety concerns.

6. Other medications and conditions matter

Certain medications may promote appetite, fluid retention or weight gain. Hypothyroidism, sleep apnea, depression, binge-eating disorder and other conditions can also affect progress.

7. Individual biology varies

People respond differently even when dose, duration and lifestyle support appear similar. Trial averages include both high and low responders.

Are dramatic transformations online representative?

Usually, you cannot determine that from a photograph.

Before accepting a transformation claim, ask:

• Is the starting weight disclosed?
• Is percentage loss reported?
• How long was treatment used?
• Was semaglutide the only intervention?
• Was bariatric surgery involved?
• Were other medications used?
• Is the dose or formulation disclosed?
• Did the person have diabetes?
• Were the photographs taken under similar conditions?
• Is the post sponsored or linked to a seller?
• Was treatment continued afterward?

The most dramatic outcomes are also the most likely to be shared. This creates selection bias: average or modest results receive less attention even though they may be more common.

A photograph cannot establish whether weight loss was medically supervised, nutritionally adequate or safely achieved.

Can semaglutide target belly fat?

Semaglutide does not selectively choose abdominal fat. When total body fat decreases, waist circumference may also decline.

In clinical trials, semaglutide reduced both body weight and waist circumference.[1,2] Where an individual loses visible fat first depends partly on genetics, sex, age and body-fat distribution.

Exercises can strengthen abdominal muscles, but they cannot force medication-induced fat loss to occur only around the stomach.

Does the face change with semaglutide?

Facial volume may decrease during substantial weight loss from any cause. The popular term “Ozempic face” is not a separate disease caused only by semaglutide.

The degree of facial change may be influenced by:

• Total weight lost
• Speed of loss
• Age
• Skin elasticity
• Genetics
• Smoking
• Sun exposure
• Hydration
• Previous weight cycling

Slower loss does not guarantee that loose skin or facial changes will not occur. Discuss unexpected swelling, severe wasting or other concerning changes with a clinician.

Will semaglutide cause loose skin?

Loose skin can occur after substantial weight loss regardless of the method used.

Factors include:

• Amount of weight lost
• Duration of prior obesity
• Age
• Genetics
• Skin elasticity
• Pregnancy history
• Smoking
• Speed of loss

Resistance training can improve muscle strength and body composition but cannot completely eliminate excess skin. Surgical evaluation may be appropriate for persistent excess skin causing rashes, hygiene problems or functional limitations after weight stabilizes.

Protecting muscle during weight loss

A smaller body is not necessarily healthier if rapid loss includes excessive lean tissue.

A clinician or registered dietitian may recommend:

• Adequate protein
• Progressive resistance exercise
• Regular physical activity
• Avoiding extreme calorie restriction
• Adequate hydration
• Evaluation of persistent weakness or fatigue

Protein requirements depend on age, body size, activity, kidney function and other medical conditions.

Changes beyond appearance

Semaglutide’s potential value should not be reduced to appearance alone.

In STEP trials, semaglutide treatment was associated with improvements in measures such as:

• Waist circumference
• Blood pressure
• Blood glucose
• Hemoglobin A1c
• Some lipid measurements
• Physical functioning[1,2]

In the SELECT cardiovascular-outcomes trial, 17,604 adults with established cardiovascular disease and overweight or obesity—but without diabetes—received semaglutide 2.4 mg or placebo. Semaglutide reduced the relative risk of cardiovascular death, nonfatal heart attack or nonfatal stroke by 20% over a mean treatment duration of approximately 33 months.[4]

That result applies to a specific high-risk population. It does not mean semaglutide produces the same cardiovascular benefit for every person taking it.

What if results are less dramatic than expected?

Do not judge your progress against the most dramatic social-media example.

A structured review should consider:

1. How long treatment has been used
2. Current dose and tolerability
3. Missed doses or supply interruptions
4. Injection technique
5. Weight and waist trends
6. Food and beverage intake
7. Physical activity and resistance exercise
8. Sleep
9. Other medications
10. Possible medical contributors

Losing 5% of starting weight can still be clinically meaningful. Even when appearance changes are subtle, improvements in metabolic risk factors may occur.

If response remains inadequate after sufficient treatment at an appropriate dose, the prescriber may reconsider the treatment plan. Do not increase the dose, inject early or combine semaglutide with another GLP-1 medication independently.

What happens when semaglutide is stopped?

Weight regain is common after discontinuation.

In the STEP 1 extension, participants who stopped semaglutide regained approximately two-thirds of their prior weight loss during the following year.[5] Many cardiometabolic improvements also moved back toward baseline.

This finding does not mean semaglutide permanently damages metabolism. It reflects the chronic biological pressures involved in obesity and the fact that the medication’s appetite effects do not continue after it leaves the body.

Before treatment, discuss:

• Expected duration
• Long-term affordability
• Insurance coverage
• Supply reliability
• Maintenance strategies
• What to do during interruptions

Do not restart a previous high dose after a prolonged interruption without consulting the prescriber.

Signs that weight loss may be too rapid or medically concerning

Faster is not always better. Contact a clinician if weight loss is accompanied by:

• Persistent vomiting
• Inability to eat or drink adequately
• Symptoms of dehydration
• Severe weakness
• Fainting
• Significant muscle loss
• Recurrent low blood sugar
• Severe constipation
• Persistent abdominal pain
• Symptoms of nutritional deficiency

Seek urgent medical care for severe abdominal pain, repeated vomiting, very little urination, yellow skin or eyes, facial swelling, difficulty breathing or severe symptoms of low blood sugar.

How to create an honest personal before-and-after record

If you want to track your own changes:

1. Use the same scale under similar conditions.
2. Record weight once or twice weekly.
3. Measure waist circumference monthly.
4. Take photographs in similar clothing, lighting, distance and posture.
5. Record the date, dose and treatment interruptions.
6. Document strength, mobility and energy.
7. Record relevant blood pressure or laboratory changes.
8. Avoid digitally altering photographs.
9. Use percentage loss rather than pounds alone.
10. Include side effects and sustainability when evaluating success.

The goal is to measure health and function—not manufacture the most dramatic visual difference.

Frequently asked questions

How much weight can you lose in three months?

There is no reliable three-month guarantee. Many patients are still progressing through introductory doses. Early results vary, and longer-term trends are more meaningful.

What is the average semaglutide before-and-after result?

In STEP 1, the average reduction was 14.9% after 68 weeks among adults without diabetes receiving semaglutide 2.4 mg plus lifestyle intervention.[1]

Can someone lose more than 20%?

Yes. Some trial participants lost at least 20%, but this was not the average outcome. Other participants lost little weight or discontinued treatment.

Why do I look similar even after losing weight?

Gradual change can be difficult to recognize, particularly when you see yourself daily. Clothing, waist measurements and standardized photographs may show changes more reliably.

Is five-percent weight loss worthwhile?

It can be clinically meaningful, especially when accompanied by improvements in blood pressure, glucose, mobility or other risk factors. Individual goals should be discussed with a clinician.

Will results remain after stopping?

Some people maintain part of their loss, but regain is common. Long-term nutrition, activity, behavioral support and an individualized maintenance plan remain important.

Bottom line

Realistic semaglutide before-and-after results should be evaluated using evidence—not a single dramatic photograph.

In STEP 1:

• Average weight loss was 14.9% after 68 weeks.
• Approximately 86% lost at least 5%.
• Approximately 69% lost at least 10%.
• Approximately 51% lost at least 15%.[1]

Your result may be higher or lower. Treatment duration, dose, medical history, diabetes status, lifestyle support, adherence and biology all influence the outcome.

Judge success using percentage weight loss, waist circumference, health measurements, physical function, side effects and sustainability. The best result is not necessarily the fastest or most photogenic—it is one that improves health and can be maintained safely.

---

Medical review: Mark Aquino, MSN, APRN, FNP-C, board-certified family nurse practitioner.

Medical disclaimer: This article provides general educational information and is not individualized medical advice. Semaglutide requires evaluation, prescribing and monitoring by a qualified healthcare professional. Do not start, stop, combine or change the dose of prescription medication based solely on online information.

References

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183.
2. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091. doi:10.1038/s41591-022-02026-4.
3. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity and type 2 diabetes: the STEP 2 trial. Lancet. 2021;397(10278):971-984. doi:10.1016/S0140-6736(21)00213-0.
4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563.
5. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. doi:10.1111/dom.14725.